Brainstorm Cell Therapeutics Inc (NAS:BCLI)
$ 2.35 0.12 (5.38%) Market Cap: 12.72 Mil Enterprise Value: 13.39 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Brainstorm Cell Therapeutics Inc looks forward to top-line results for its ALS Phase 3 program Transcript

Jan 15, 2020 / NTS GMT
Release Date Price: $65.25 (+0.23%)
Christine Corrado
Proactive Investors Limited - Moderator

Hello, and welcome to day two here at the biotech showcase 2020 in San Francisco. I am Christine Corrado with Proactive. Joining me right now is Ralph Kern. He is the COO and Chief Medical Officer at Brainstorm Cell Therapeutics. Ralf, great to see you.

Ralph Kearney
Brainstorm Cell Therapeutics - COO and Chief Medical Officer

Thanks, Christine. Pleasure to be here.

Christine Corrado
Proactive Investors Limited - Moderator

Ralf, we talked about a year ago in this same exact place. First off just remind investors about the company.

Ralph Kearney;Christine Corrado
Brainstorm Cell Therapeutics - COO and Chief Medical Officer;Proactive Investors Limited

Yes, we're a biotech company that's focused on developing cellular therapeutics for neurodegenerative diseases. And we have ALS program, which is in Phase 3, fully enrolled and we're going to have data in the fourth quarter of this year.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot